This is a working overview of synaptogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Two approaches to synthesis are used commercially. In chemical synthesis, aspartame is synthesized using the L enantiomer of phenylalanine. The two carboxyl groups of aspartic acid are joined into an anhydride, and the amino group is protected with a formyl group as the formamide, by treatment of aspartic acid with a mixture of formic acid and acetic anhydride. Phenylalanine is converted to its methyl ester and combined with the N-formyl aspartic anhydride; then the protecting group is removed from aspartic nitrogen by acid hydrolysis. The drawback of this technique is that a byproduct, the bitter-tasting β-form, is produced when the wrong carboxyl group from aspartic acid anhydride links to phenylalanine, with desired and undesired isomer forming in a 4:1 ratio. Another process used to synthesize aspartame is to use an enzyme from Bacillus thermoproteolyticus to catalyze the condensation of chemically altered amino acids. This will produce high yields of aspartame without the β-form byproduct. A variant of this method, which has not been used commercially, uses unmodified aspartic acid but produces low yields. Methods for directly producing aspartyl-phenylalanine by enzymatic means, followed by chemical methylation, have also been tried but not scaled for industrial production.
Agilent ChemStation is a software package to control Agilent liquid chromatography, gas chromatography, and ultraviolet-visible spectroscopy systems such as the 1050, 1100 and 1200 Series HPLC system and the 8453 and 8454 single-beam diode array detector spectrophotometers. It is an evolution of the Hewlett-Packard ChemStation System. Two versions are available: one ("online") in connection with the modules of the HPLC chain is designed to control instruments and run experiments, and the other ("offline"), without a connection with the HPLC chain, is designed to analyze data. ChemStation is structured around a number of registers. Two of the more important registers are CHROMREG and CHROMRES, the chromatographic data registers. Other special registers exist for the UV-vis implementation of the software. ChemStation has a command line interpreter and can run macros. Those macros are files grouping a set of commands. These files possess a .mac extension. ChemStation can import analysis lists and export result files in XML by adding new lines to the ChemStation.ini configuration file. This is a feature to implement the connection with a Laboratory information management system (LIMS).
Elizabeth Murphy Topp is an American pharmaceutical scientist and educator known for her work in solid‐state chemical stability of proteins and peptides. In 2000s Topp introduced solid-state hydrogen-deuterium exchange as the method for stability characterization of lyophilized biopharmaceutical formulations. She is the Chief Scientific Officer at National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland since September 2019. Topp was on the faculty at the University of Kansas Department of Pharmaceutical Chemistry from 1986 to 2009. She has been the Head and Dane O. Kildsig Chair at the Department of Industrial and Physical Chemistry at Purdue University College of Pharmacy from 2009 to 2017. Topp has been elected a fellow of American Association of Pharmaceutical Scientists in 2010 for "making sustained remarkable scholarly and research contributions to the pharmaceutical sciences". In 2015 Topp co-founded, with Alina Alexeenko, an industry-university consortium LyoHUB for advancing pharmaceutical lyophilization technology. Topp earned her B.S. in Chemical Engineering form the University of Delaware, M.E. in Chemical and Biochemical Engineering from the University of Pennsylvania and a Ph.D. in Pharmaceutics from University of Michigan.
Sources: en.wikipedia.org
=== Female genital mutilation === The most prevalent form of non-consensual genital alteration is that of female genital mutilation. This mostly involves the partial or complete removal of the vulva. Female genital mutilation is carried out in thirty countries in Africa and Asia with more than 200 million girls being affected, and some women (as of 2018). Nearly all of the procedures are carried out on young girls. The practices are also carried out globally among migrants from these areas. Female genital mutilation is claimed to be mostly carried out for cultural traditional reasons. According to the research conducted under In the Name of Tradition, FGM/C is more common in Sunni countries and less common in Shia societies. FGM/C can have harmful effects on their physical and mental health. Various official and unofficial research reports also confirm these complications. In its various reports, the World Health Organization has considered FGM/C as an action that endangers women's health in various ways. This organization stated in a report published in January 2023 that FGM/C has no health benefits, and it harms girls and women in many ways. It involves removing and damaging healthy and normal female genital tissue, and it interferes with the natural functions of girls' and women's bodies. Although all forms of FGM/C are associated with increased risk of health complications, the risk is greater with more severe forms of FGM/C.
== Types == Alkaptonuria Aspartylglucosaminuria Branched-chain keto acid dehydrogenase kinase deficiency Methylmalonic acidemia Maple syrup urine disease Homocystinuria Tyrosinemia Trimethylaminuria Hartnup disease Biotinidase deficiency Ornithine carbamoyltransferase deficiency Carbamoyl-phosphate synthase I deficiency disease Citrullinemia Hyperargininemia Hyperhomocysteinemia Hypermethioninemia Hyperlysinemias Nonketotic hyperglycinemia Propionic acidemia Hyperprolinemia
ModDB ( MOD-dee-BEE) is a website that focuses on general video game modding. It was founded in 2002 by Scott "INtense!" Reismanis. As of August 2026, the ModDB site has received over 2 billion views, has more than 36,000 modifications registered, and has hosted more than 382 million downloads. A spin-off website, IndieDB, was launched in 2010 and focuses on indie games and news. The website has retained a mostly traditional user interface, with its overall layout, dark red theme, and design remaining largely unchanged since 2008.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.